COVID-19 Vaccines: Moderna And Pfizer-BioNTech Use Varied By Urban, Rural Counties

Katherine Wen; Daniel A Harris; Preeti Chachlani; Kaleen N Hayes; Ellen McCarthy; Andrew R Zullo; Renae L Smith-Ray; Tanya Singh; Djeneba Audrey Djibo; Cheryl N McMahill-Walraven; Jeffrey Hiris; Rena M Conti; Jonathan Gruber; Vincent Mor

doi:10.1377/hlthaff.2023.00813

COVID-19 Vaccines: Moderna And Pfizer-BioNTech Use Varied By Urban, Rural Counties

Health Aff (Millwood). 2024 May;43(5):659-665. doi: 10.1377/hlthaff.2023.00813.

Authors

Affiliations

¹ Katherine Wen (katherine.j.wen@vanderbilt.edu), Vanderbilt University, Nashville, Tennessee.
² Daniel A. Harris, Brown University, Providence, Rhode Island.
³ Preeti Chachlani, Brown University.
⁴ Kaleen N. Hayes, Brown University.
⁵ Ellen McCarthy, Harvard University, Boston, Massachusetts.
⁶ Andrew R. Zullo, Brown University.
⁷ Renae L. Smith-Ray, Walgreens, Deerfield, Illinois.
⁸ Tanya Singh, Walgreens.
⁹ Djeneba Audrey Djibo, CVS Health, Blue Bell, Pennsylvania.
¹⁰ Cheryl N. McMahill-Walraven, CVS Health.
¹¹ Jeffrey Hiris, Brown University.
¹² Rena M. Conti, Boston University, Boston, Massachusetts.
¹³ Jonathan Gruber, Massachusetts Institute of Technology, Cambridge, Massachusetts.
¹⁴ Vincent Mor, Brown University.

Abstract

We investigated county-level variation in mRNA COVID-19 vaccine use among Medicare beneficiaries throughout the United States. There was greater use of Pfizer-BioNTech vaccines than Moderna vaccines in urban areas for first and booster doses.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Aged
BNT162 Vaccine
COVID-19 Vaccines*
COVID-19* / prevention & control
Female
Humans
Male
Medicare* / statistics & numerical data
Rural Population*
SARS-CoV-2
United States
Urban Population* / statistics & numerical data

Substances

COVID-19 Vaccines
BNT162 Vaccine

Grants and funding

U54 AG063546/AG/NIA NIH HHS/United States